AMYVID Drug Patent Profile
✉ Email this page to a colleague
When do Amyvid patents expire, and what generic alternatives are available?
Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.
This drug has forty-nine patent family members in thirty-two countries.
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Amyvid
Amyvid was eligible for patent challenges on April 6, 2016.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 30, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for AMYVID
International Patents: | 49 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Clinical Trials: | 38 |
Patent Applications: | 248 |
What excipients (inactive ingredients) are in AMYVID? | AMYVID excipients list |
DailyMed Link: | AMYVID at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for AMYVID
Generic Entry Date for AMYVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AMYVID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Invicro | Phase 1 |
Elisa Konofagou | N/A |
National Institute on Aging (NIA) | N/A |
Pharmacology for AMYVID
Drug Class | Radioactive Diagnostic Agent |
Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for AMYVID
AMYVID is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMYVID is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting AMYVID
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
International Patents for AMYVID
When does loss-of-exclusivity occur for AMYVID?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07243712
Estimated Expiration: See Plans and Pricing
Austria
Patent: 9060
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0710225
Estimated Expiration: See Plans and Pricing
Canada
Patent: 44530
Estimated Expiration: See Plans and Pricing
China
Patent: 1522624
Estimated Expiration: See Plans and Pricing
Costa Rica
Patent: 329
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0120135
Estimated Expiration: See Plans and Pricing
Patent: 0170857
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 13048
Estimated Expiration: See Plans and Pricing
Patent: 19048
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 99109
Estimated Expiration: See Plans and Pricing
Patent: 63392
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 088783
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 7898
Estimated Expiration: See Plans and Pricing
Patent: 0870389
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 99109
Estimated Expiration: See Plans and Pricing
Patent: 63391
Estimated Expiration: See Plans and Pricing
Patent: 63392
Estimated Expiration: See Plans and Pricing
Guatemala
Patent: 0800201
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 32660
Estimated Expiration: See Plans and Pricing
Patent: 300028
Estimated Expiration: See Plans and Pricing
Israel
Patent: 3567
Estimated Expiration: See Plans and Pricing
Japan
Patent: 90954
Estimated Expiration: See Plans and Pricing
Patent: 09532349
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 63392
Estimated Expiration: See Plans and Pricing
Luxembourg
Patent: 232
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 08012527
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 0887
Estimated Expiration: See Plans and Pricing
Norway
Patent: 2090
Estimated Expiration: See Plans and Pricing
Patent: 18030
Estimated Expiration: See Plans and Pricing
Patent: 084590
Estimated Expiration: See Plans and Pricing
Poland
Patent: 99109
Estimated Expiration: See Plans and Pricing
Patent: 63392
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 99109
Estimated Expiration: See Plans and Pricing
Patent: 63392
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 222
Estimated Expiration: See Plans and Pricing
Patent: 171
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 3338
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 99109
Estimated Expiration: See Plans and Pricing
Patent: 63392
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 0807955
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1376807
Estimated Expiration: See Plans and Pricing
Patent: 080106564
Estimated Expiration: See Plans and Pricing
Spain
Patent: 78785
Estimated Expiration: See Plans and Pricing
Patent: 28882
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 99366
Estimated Expiration: See Plans and Pricing
Patent: 0838852
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 802
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering AMYVID around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 1999109 | See Plans and Pricing | |
Taiwan | I399366 | See Plans and Pricing | |
Mexico | 2008012527 | DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCION DE IMAGENES DE LAS MISMAS. (STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES.) | See Plans and Pricing |
Ukraine | 97802 | СТИРИЛПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК;СТИРИЛПІРИДИНОВІ ПОХІДНІ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ЗВ'ЯЗУВАННЯ І ВІЗУАЛІЗАЦІЇ АМІЛОЇДНИХ БЛЯШОК (STYRYLPYRIDINE COMPOUNDS USEFUL AND USE THEREOF IN IMAGING AMYLOID DEPOSITS) | See Plans and Pricing |
Spain | 2628882 | See Plans and Pricing | |
Spain | 2378785 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AMYVID
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1999109 | 2013/028 | Ireland | See Plans and Pricing | PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
1999109 | 139 5017-2013 | Slovakia | See Plans and Pricing | PRODUCT NAME: FLORBETAPIR ( 18 F); REGISTRATION NO/DATE: EU/1/12/805 20130114 |
1999109 | PA2013016 | Lithuania | See Plans and Pricing | PRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
1999109 | SPC/GB13/040 | United Kingdom | See Plans and Pricing | PRODUCT NAME: FLORBETAPIR (18F) ((E)-4-(2-(6-(2-(2-(2-((18F)-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL(18F); REGISTERED: UK EU/1/12/805 20130117 )VINYL)-N-METHYL BENZENAMINE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY FLORBETAPIR |
1999109 | 92232 | Luxembourg | See Plans and Pricing | PRODUCT NAME: FLORBETAPIR (18 F) |
1999109 | C300600 | Netherlands | See Plans and Pricing | PRODUCT NAME: FLORBETAPIR ( SUP 18 /SUP F); REGISTRATION NO/DATE: EU/1/12/805 20130114 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |